Tumor Boards

Metastatic breast cancer

Genomic Panel Testing – Tumor Mutational Load (December 2016)

  • Tumor mutational load (TML) is a measure of the total number of non-synonymous mutations per coding area
    • A non-synonymous mutation is a change in the DNA sequence that results in the alteration of an amino acid
  • Emerging data suggests TML could be used to predict response to immune checkpoint inhibitors across various tumor sites
  • High TML correlates to better response to immunotherapy.
tumor board image


1. https://www.carismolecularintelligence.com/wp-content/uploads/2016/12/TN0291-v1_Total-Mutational-Load-Immunotherapy-REVERSED-PAGES.pdf
2. http://mct.aacrjournals.org/content/16/11/2598